Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Cetuximab With or Without Irinotecan in Irinotecan-Refractory Colorectal Cancer
NCT00077298Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2003
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and KL-140 in colorectal cancer (CRC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Time to tumor progression up to 3 years. Started Dec 2003; status: completed.
02
Drugs
bevacizumabKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00077298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077298.